Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision by the U.S. Food and Drug Administration (FDA) to approve Sanofi ...

Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young childrenExpanded approval includes children aged one ...

Eligibility now includes ages 1–7 years with stage 2 T1D, defined by multiple diabetes autoantibodies plus dysglycemia ...

More and more patients are developing type 2 diabetes while still young. The diagnosis may lead to a life of disease.

Tzield is a CD3-directed monoclonal antibody drug that was first approved in the US in November 2022 to delay the onset of ...

Researchers identify genetic markers that predict the rate of β-cell failure in type 1 diabetes, facilitating earlier, personalized care strategies Type 1 diabetes (T1D) is an autoimmune condition ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal gastrointestinal cancers, with a rising global incidence; indeed, the worldwide burden of ...

A genetic predisposition to having lower insulin production and less healthy fat distribution are major causes of early-onset type 2 diabetes in British Asian people. According to research, these ...

Stress does no one — not even your insulin-producing cells — any good. Researchers from Osaka Metropolitan University have identified a gene that, when activated by metabolic stress, damages ...